A5002274771- PI3K/AKT/mTOR signaling in cancer
- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- Cancer Immunotherapy and Biomarkers
- Cytokine Signaling Pathways and Interactions
- Bladder and Urothelial Cancer Treatments
- Ferroptosis and cancer prognosis
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
Hospital Del Mar
2022-2024
Municipal Institute for Medical Research
2022-2024
Transforming growth factor beta (TGFβ) and activin A suppress natural killer (NK) cell function proliferation, limiting the efficacy of adoptive NK therapies. Inspired by partial resistance to TGFβ cells with SMAD4 haploinsufficiency, we used CRISPR–Cas9 for knockout in human cells. Here show that SMAD4KO were resistant inhibition, retaining their cytotoxicity, cytokine secretion interleukin-2/interleukin-15-driven proliferation. They showed enhanced tumor penetration control, both as...
Abstract In patients with trastuzumab-resistant HER2-positive breast cancer, the combination of everolimus (mTORC1 inhibitor) trastuzumab failed to show a clinically significant benefit. However, mTOR inhibition and antibody–drug conjugate (ADC) trastuzumab-emtansine (T-DM1) remains unexplored. We tested T-DM1 plus in broad panel cancer cell lines. The was superior alone four lines (HCC1954, SKBR3, EFM192A, MDA-MB-36) two cultures from primary tumor cells derived patient-derived xenografts...
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
<div>Abstract<p>In patients with trastuzumab-resistant HER2-positive breast cancer, the combination of everolimus (mTORC1 inhibitor) trastuzumab failed to show a clinically significant benefit. However, mTOR inhibition and antibody–drug conjugate (ADC) trastuzumab-emtansine (T-DM1) remains unexplored. We tested T-DM1 plus in broad panel cancer cell lines. The was superior alone four lines (HCC1954, SKBR3, EFM192A, MDA-MB-36) two cultures from primary tumor cells derived...
<div>Abstract<p>In patients with trastuzumab-resistant HER2-positive breast cancer, the combination of everolimus (mTORC1 inhibitor) trastuzumab failed to show a clinically significant benefit. However, mTOR inhibition and antibody–drug conjugate (ADC) trastuzumab-emtansine (T-DM1) remains unexplored. We tested T-DM1 plus in broad panel cancer cell lines. The was superior alone four lines (HCC1954, SKBR3, EFM192A, MDA-MB-36) two cultures from primary tumor cells derived...